Depression is one of the most common mental health conditions worldwide and reduces the quality of life of millions of people. Alongside established treatments such as psychotherapy and antidepressants, interest in complementary approaches has grown over recent years — including omega-3 fatty acid supplementation. Epidemiological observations had long suggested a connection between low fish consumption and higher rates of depression.
Today, an extensive body of clinical research exists that more precisely identifies which omega-3 fatty acid plays the decisive role in mood and depressive symptoms: it is primarily EPA — and not DHA.
TL;DR — The key points at a glance
- A meta-analysis (Liao 2019) with 2,160 participants showed: EPA-dominant formulations (≥ 60% EPA) achieve an effect size of SMD = −1.03 on depressive symptoms.
- DHA-dominant products showed no significant antidepressant effect in this analysis.
- The antidepressant effect of omega-3 is EPA-dependent — the EPA:DHA ratio of the product is therefore crucial.
- Significant effects were observed in studies after 4–12 weeks of daily intake of 1–2 g EPA.
- Omega-3 does not replace psychiatric treatment but can be used as a complementary measure in consultation with a doctor.
EPA and DHA: Two Fatty Acids with Different Effects
Omega-3 fatty acids from fish oil or algae oil consist mainly of two long-chain fatty acids: EPA (eicosapentaenoic acid, 20:5n-3) and DHA (docosahexaenoic acid, 22:6n-3). Both are important for health, but differ in their emphasis:
- DHA is the structural building block of nerve cell membranes in the brain and according to EFSA contributes to normal brain function (from 250 mg/day). More in the article Omega-3 for the Brain.
- EPA acts primarily as an inflammation modulator: it is the precursor of anti-inflammatory signalling molecules (3-series eicosanoids, E-series resolvins) and inhibits the production of pro-inflammatory arachidonic acid metabolites. In the area of mental health, EPA is today considered the pharmacologically more active fatty acid.
This difference is highly clinically relevant: the choice of omega-3 product — particularly the EPA:DHA ratio — influences, according to current research, whether measurable effects on mood and depression can be expected.
Biochemical background information on EPA can be found in the foundational article on EPA (Eicosapentaenoic Acid).
The Central Meta-Analysis: Liao et al., Translational Psychiatry 2019
The most comprehensive and methodologically rigorous analysis to date on the question of "omega-3 for depression" appeared in 2019 in the prestigious journal Translational Psychiatry. Liao and colleagues evaluated 26 double-blind, placebo-controlled, randomised trials with a total of 2,160 participants with diagnosed depression.
The central findings of this meta-analysis:
- Overall effect: omega-3 showed a significant antidepressant effect across all studies (SMD = −0.28; P = 0.004). This corresponds to a small to moderate effect.
- Pure EPA formulations (≤ 1 g/day EPA, no DHA): SMD = −0.50 (P = 0.003) — a moderate to large effect.
- EPA-dominant formulations (≥ 60% EPA content): SMD = −1.03 — a large effect that is clinically relevant.
- DHA-dominant formulations: no significant antidepressant effect demonstrable.
The researchers' conclusion was clear: the antidepressant effect of omega-3 is EPA-dependent. DHA-dominant products showed no significant effect on depressive symptoms in this meta-analysis.
Depression: 26 Double-Blind, Placebo-Controlled Studies
In a meta-analysis with 2,160 participants, a significant overall effect on depressive symptoms was found (SMD = −0.28; P = 0.004). Pure EPA formulations (≤ 1 g/day) achieved SMD = −0.50 (P = 0.003). EPA-dominant formulations (≥ 60% EPA) showed SMD = −1.03. DHA-dominant formulations: no significant effect.
EPA vs. DHA in Depression: A Clear Pattern
The finding of the Liao meta-analysis does not stand alone. Earlier reviews, including analyses by Sublette et al. (2011) and Martins (2009), had already identified a threshold of around 60% EPA content in the formulation as decisive for antidepressant effects.
Why does EPA act more strongly on mood than DHA?
Possible Mechanisms of EPA in Depression
Although the precise mechanisms are still being studied, several plausible biological explanations exist:
- Neuroinflammation: inflammatory markers such as CRP, IL-6 and TNF-alpha are frequently elevated in depression. EPA can inhibit the production of pro-inflammatory eicosanoids (from arachidonic acid) while simultaneously forming anti-inflammatory resolvins — both can dampen neuronal inflammatory processes.
- Serotonin system: EPA appears to influence the function of serotonin transporters and receptors, which could improve serotonin signalling — the most important neurotransmitter in the context of mood.
- HPA axis: EPA may modulate the stress hormone axis (hypothalamic-pituitary-adrenal axis), which is frequently dysregulated in depression.
- Neuronal plasticity: EPA possibly promotes the release of neurotrophic factors such as BDNF (brain-derived neurotrophic factor), which is important for neuronal growth and mood regulation.
No EFSA Claim for Depression
There is currently no EFSA-approved health claim for omega-3 in depression or mental health. The effects described here are based on clinical study results and do not replace a psychiatric diagnosis or treatment. Omega-3 may — with the appropriate formulation — play a complementary role, but is not an antidepressant.
EPA Formulations Compared: What the EPA:DHA Ratio Means
For the clinical context of depression, the EPA:DHA ratio of a product is decisive. Many standard fish oil products have a ratio of around 3:2 (EPA:DHA) or even 1:2 — which, according to the Liao analysis, may not be sufficient to achieve significant antidepressant effects. For this purpose, specifically high-concentration EPA formulations (pure EPA or ≥ 60% EPA content) are the best-researched options.
| Formulation type | EPA content | Effect on depressive symptoms (Liao 2019) | Effect size (SMD) |
|---|---|---|---|
| Pure EPA | 100% EPA, no DHA | Significant | −0.50 (P = 0.003) |
| EPA-dominant | ≥ 60% EPA content | Strongly significant | −1.03 |
| Mixed (standard) | approx. 40–60% EPA | Inconsistent | Variable |
| DHA-dominant | < 40% EPA | No effect | Not significant |
Omega-3 as an Add-On to Antidepressants
An important aspect of the research concerns whether omega-3 is also effective as an add-on to existing antidepressant therapy. Several studies have examined EPA+DHA as a supplement to antidepressants (SSRIs).
A meta-analysis by Hallahan et al. (2016) in The British Journal of Psychiatry found evidence of additive effects when omega-3 was added to ongoing antidepressant treatment. These findings make omega-3 — in EPA-dominant formulation — an interesting topic for specialist discussions with psychiatrists and treating doctors. Autonomous substitution or reduction of medication is explicitly not recommended.
Depression and Omega-3 Status: The Connection
Several studies have found that people with depression have, on average, lower blood EPA and DHA levels than people without depression. Whether this low level is a cause, consequence or accompanying symptom of depression cannot be conclusively established from observational studies.
What is clear: a low omega-3 index (below 4%) is an independent risk factor that in several studies was associated with poorer mental health. Other physical and psychological signs that may indicate omega-3 deficiency are described in the article Omega-3 Deficiency Symptoms.
Particularly interesting is the connection in perinatal depression (postnatal depression). DHA requirements increase considerably during pregnancy — maternal DHA levels may have fallen significantly after birth, which possibly increases vulnerability to depressive episodes. Potential preventive connections here are being further researched.
Mood Changes Beyond Clinical Depression
Besides clinically diagnosed depression, studies have also examined omega-3 in subclinical mood changes, irritability and general wellbeing. The findings are less uniform than in clinical depression — partly because subclinical mood states are harder to measure and the studies are methodologically more heterogeneous.
A 2014 study published in the journal Brain, Behavior, and Immunity with young healthy adults found after 12 weeks of 2.5 g omega-3 daily a significant reduction in anxiety symptoms and inflammatory markers compared to the placebo group.
Such findings in healthy populations should be considered methodologically — but they point to potential effects beyond clinical diagnoses as well.
Summary: What the Research Says
Studies show that EPA-dominant omega-3 can have a moderate to large antidepressant effect in diagnosed depression — particularly with EPA-dominant formulations (≥ 60% EPA content). DHA-dominant products showed no significant effect in the most important meta-analysis. Omega-3 is not a substitute for psychiatric treatment but can play a complementary role — always in consultation with a doctor.
Dosage: What Studies Have Used
In most studies showing antidepressant effects, doses of between 1 g and 2 g EPA daily were used. The pure EPA formulations identified in the Liao meta-analysis as particularly effective were at ≤ 1 g EPA/day — which seems surprisingly low, but may be due to greater bioavailability without DHA competition.
For EPA-dominant formulations (≥ 60% EPA), studies typically used daily doses of 1–3 g omega-3, with the EPA content being at least 600–1,800 mg.
A detailed dosage overview can be found in the article on Omega-3 Dosage per Day.
What to Look for When Choosing a Product
Anyone wanting to use omega-3 specifically for potential effects on mood and mental wellbeing should look for the following when purchasing:
- EPA:DHA ratio: at least 2:1 EPA:DHA, preferably ≥ 3:1 or pure EPA
- Absolute EPA amount: at least 500–1,000 mg EPA per daily dose
- Form: triglyceride form (TG) or re-esterified triglyceride (rTG) has better bioavailability than ethyl ester (EE)
- Oxidation protection: TOTOX value as low as possible (below 10) — fresh oil with antioxidants (e.g. vitamin E)
- Quality certificates: IFOS, Friend of the Sea or comparable testing
Frequently Asked Questions
Can omega-3 cure depression?
No. Omega-3 is not a cure for depression and does not replace psychiatric treatment. Studies do show, however, that EPA-dominant omega-3 can significantly reduce depressive symptoms in controlled trials — as a complementary measure alongside ongoing therapy. With a diagnosed depression, medical supervision is absolutely essential.
Why does DHA not work for depression, but EPA does?
DHA is primarily a structural building block of brain membranes and influences cognitive functions more. EPA, by contrast, acts strongly as an inflammation modulator — and since inflammatory processes (neuroinflammation) play an important role in depression, EPA appears to be the pharmacologically more active substance in mood regulation. Furthermore, EPA and DHA compete for the same metabolic enzymes — too much DHA can reduce EPA availability in tissues.
Which omega-3 product is suitable for depression?
Studies have preferentially used EPA-dominant products with at least 60% EPA content or pure EPA formulations. Standard fish oil capsules with a 3:2 EPA:DHA ratio may suffice in individual cases but are less well studied for this purpose. Specific product recommendations should be discussed with a doctor or pharmacist.
How long does it take for omega-3 to act on mood?
In most clinical studies, significant effects were observed after 4–12 weeks of regular intake. An immediate effect is biochemically unlikely, as the fatty acid composition in cell membranes takes weeks to change. For a meaningful personal assessment, intake should be maintained consistently for at least 6–8 weeks.
Is omega-3 safe — even alongside antidepressants?
Omega-3 fatty acids are considered well tolerated at usual doses (up to 3 g/day EPA+DHA). At higher doses and with simultaneous intake of anticoagulants (e.g. warfarin, aspirin, some antidepressants), a doctor should be informed, as omega-3 can mildly affect blood clotting. The key rule: before starting supplementation with a psychiatric condition, always consult the treating doctor.
Important warning for depression
Depression is a serious condition that requires professional treatment. Omega-3 may play a complementary role based on the evidence — but is not a substitute for psychotherapy, antidepressants or psychiatric care. In acute depression or suicidal thoughts, contact a doctor or crisis helpline immediately.
Medical disclaimer
This article is for general information purposes only and does not replace medical advice. All health claims are based on published studies and scientific meta-analyses. There is currently no EFSA-approved health claim for omega-3 in depression or mental health. Dietary supplements are not a substitute for a balanced diet and a healthy lifestyle.
This article is part of our health overview, which presents all scientifically supported areas of omega-3 benefit — from heart and brain to inflammation and eyes.